Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients
Objective. The aim of this study was to assess the efficacy of anti-TNF-alpha therapy in refractory uveitis due to Behcet's disease (BD). Methods. We performed a multicentre study of 124 patients with BD uveitis refractory to conventional treatment including high-dose corticosteroids and at lea...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2014 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | r-FISABIO. Repositorio Institucional de Producción Científica |
| OAI Identifier: | oai:fisabio.fundanetsuite.com:p14939 |
| Acceso en línea: | https://fisabio.portalinvestigacion.com/publicaciones/14939 |
| Access Level: | acceso abierto |
| Palabra clave: | Behcet's disease uveitis anti-TNF therapy |
| id |
ES_0e72ed0e8d13bceac00d80d35e2b36b5 |
|---|---|
| oai_identifier_str |
oai:fisabio.fundanetsuite.com:p14939 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patientsCalvo-Rio, VBlanco, RSanchez-Burson, JMesquida, MAdan, AHernandez, MVGarfella, MHPascual, EVMartinez-Costa, LSellas-Fernandez, AComa, MCDiaz-Llopis, MGallego, RSalom, DSerrano, JLGOrtego, NHerreras, JMFonollosa, AGarcia-Aparicio, AMMaiz, OBlanco, ATorre, IFernandez-Espartero, CJovani, VPeiteado-Lopez, DPato, ECruz, JFernandez-Cid, CAurrecoechea, EGarcia, MCaracuel, MAMontilla, CAtanes, AHernandez, FFInsua, SGonzalez-Suarez, SSanchez-Andrade, AGamero, FLinares, LRomero-Bueno, FGarcia, AJAlmodovar, RMinguez, ECubero, CCOlive, AVazquez, JMoreno, ORJimenez-Zorzo, FManero, JFernandez, SMRueda-Gotor, JGonzalez-Gay, MABehcet's diseaseuveitisanti-TNF therapyObjective. The aim of this study was to assess the efficacy of anti-TNF-alpha therapy in refractory uveitis due to Behcet's disease (BD). Methods. We performed a multicentre study of 124 patients with BD uveitis refractory to conventional treatment including high-dose corticosteroids and at least one standard immunosuppressive agent. Patients were treated for at least 12 months with infliximab (IFX) (3-5 mg/kg at 0, 2 and 6 weeks and then every 4-8 weeks) or adalimumab (ADA) (usually 40 mg every 2 weeks). The main outcome measures were degree of anterior and posterior chamber inflammation, visual acuity, macular thickness and immunosuppression load. Results. Sixty-eight men and 56 women (221 affected eyes) were studied. The mean age was 38.6 years (S.D. 10.4). HLA-B51 was positive in 66.1% of patients and uveitis was bilateral in 78.2%. IFX was the first biologic agent in 77 cases (62%) and ADA was first in 47 (38%). In most cases anti-TNF-alpha drugs were used in combination with conventional immunosuppressive drugs. At the onset of anti-TNF-alpha therapy, anterior chamber and vitreous inflammation was observed in 57% and 64.4% of patients, respectively. In both conditions the damage decreased significantly after 1 year. At baseline, 50 patients (80 eyes) had macular thickening [optical coherence tomography (OCT) >250 mu m] and 35 (49 eyes) had cystoid macular oedema (OCT > 300 mu m) that improved from 420 mm (S.D. 119.5) at baseline to 271 mu m (S.D. 45.6) at month 12 (P < 0.01). The best-corrected visual acuity and the suppression load also showed significant improvement. After 1 year of follow-up, 67.7% of patients were inactive. Biologic therapy was well tolerated in most cases. Conclusion. Anti-TNF-alpha therapy is effective and relatively safe in refractory BD uveitis.OXFORD UNIV PRESS2014info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/14939RHEUMATOLOGYISSN: 14620324ISSNe: 14620332reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p149392026-06-11T12:45:17Z |
| dc.title.none.fl_str_mv |
Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients |
| title |
Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients |
| spellingShingle |
Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients Calvo-Rio, V Behcet's disease uveitis anti-TNF therapy |
| title_short |
Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients |
| title_full |
Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients |
| title_fullStr |
Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients |
| title_full_unstemmed |
Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients |
| title_sort |
Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients |
| dc.creator.none.fl_str_mv |
Calvo-Rio, V Blanco, R Sanchez-Burson, J Mesquida, M Adan, A Hernandez, MV Garfella, MH Pascual, EV Martinez-Costa, L Sellas-Fernandez, A Coma, MC Diaz-Llopis, M Gallego, R Salom, D Serrano, JLG Ortego, N Herreras, JM Fonollosa, A Garcia-Aparicio, AM Maiz, O Blanco, A Torre, I Fernandez-Espartero, C Jovani, V Peiteado-Lopez, D Pato, E Cruz, J Fernandez-Cid, C Aurrecoechea, E Garcia, M Caracuel, MA Montilla, C Atanes, A Hernandez, FF Insua, S Gonzalez-Suarez, S Sanchez-Andrade, A Gamero, F Linares, L Romero-Bueno, F Garcia, AJ Almodovar, R Minguez, E Cubero, CC Olive, A Vazquez, J Moreno, OR Jimenez-Zorzo, F Manero, J Fernandez, SM Rueda-Gotor, J Gonzalez-Gay, MA |
| author |
Calvo-Rio, V |
| author_facet |
Calvo-Rio, V Blanco, R Sanchez-Burson, J Mesquida, M Adan, A Hernandez, MV Garfella, MH Pascual, EV Martinez-Costa, L Sellas-Fernandez, A Coma, MC Diaz-Llopis, M Gallego, R Salom, D Serrano, JLG Ortego, N Herreras, JM Fonollosa, A Garcia-Aparicio, AM Maiz, O Blanco, A Torre, I Fernandez-Espartero, C Jovani, V Peiteado-Lopez, D Pato, E Cruz, J Fernandez-Cid, C Aurrecoechea, E Garcia, M Caracuel, MA Montilla, C Atanes, A Hernandez, FF Insua, S Gonzalez-Suarez, S Sanchez-Andrade, A Gamero, F Linares, L Romero-Bueno, F Garcia, AJ Almodovar, R Minguez, E Cubero, CC Olive, A Vazquez, J Moreno, OR Jimenez-Zorzo, F Manero, J Fernandez, SM Rueda-Gotor, J Gonzalez-Gay, MA |
| author_role |
author |
| author2 |
Blanco, R Sanchez-Burson, J Mesquida, M Adan, A Hernandez, MV Garfella, MH Pascual, EV Martinez-Costa, L Sellas-Fernandez, A Coma, MC Diaz-Llopis, M Gallego, R Salom, D Serrano, JLG Ortego, N Herreras, JM Fonollosa, A Garcia-Aparicio, AM Maiz, O Blanco, A Torre, I Fernandez-Espartero, C Jovani, V Peiteado-Lopez, D Pato, E Cruz, J Fernandez-Cid, C Aurrecoechea, E Garcia, M Caracuel, MA Montilla, C Atanes, A Hernandez, FF Insua, S Gonzalez-Suarez, S Sanchez-Andrade, A Gamero, F Linares, L Romero-Bueno, F Garcia, AJ Almodovar, R Minguez, E Cubero, CC Olive, A Vazquez, J Moreno, OR Jimenez-Zorzo, F Manero, J Fernandez, SM Rueda-Gotor, J Gonzalez-Gay, MA |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Behcet's disease uveitis anti-TNF therapy |
| topic |
Behcet's disease uveitis anti-TNF therapy |
| description |
Objective. The aim of this study was to assess the efficacy of anti-TNF-alpha therapy in refractory uveitis due to Behcet's disease (BD). Methods. We performed a multicentre study of 124 patients with BD uveitis refractory to conventional treatment including high-dose corticosteroids and at least one standard immunosuppressive agent. Patients were treated for at least 12 months with infliximab (IFX) (3-5 mg/kg at 0, 2 and 6 weeks and then every 4-8 weeks) or adalimumab (ADA) (usually 40 mg every 2 weeks). The main outcome measures were degree of anterior and posterior chamber inflammation, visual acuity, macular thickness and immunosuppression load. Results. Sixty-eight men and 56 women (221 affected eyes) were studied. The mean age was 38.6 years (S.D. 10.4). HLA-B51 was positive in 66.1% of patients and uveitis was bilateral in 78.2%. IFX was the first biologic agent in 77 cases (62%) and ADA was first in 47 (38%). In most cases anti-TNF-alpha drugs were used in combination with conventional immunosuppressive drugs. At the onset of anti-TNF-alpha therapy, anterior chamber and vitreous inflammation was observed in 57% and 64.4% of patients, respectively. In both conditions the damage decreased significantly after 1 year. At baseline, 50 patients (80 eyes) had macular thickening [optical coherence tomography (OCT) >250 mu m] and 35 (49 eyes) had cystoid macular oedema (OCT > 300 mu m) that improved from 420 mm (S.D. 119.5) at baseline to 271 mu m (S.D. 45.6) at month 12 (P < 0.01). The best-corrected visual acuity and the suppression load also showed significant improvement. After 1 year of follow-up, 67.7% of patients were inactive. Biologic therapy was well tolerated in most cases. Conclusion. Anti-TNF-alpha therapy is effective and relatively safe in refractory BD uveitis. |
| publishDate |
2014 |
| dc.date.none.fl_str_mv |
2014 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://fisabio.portalinvestigacion.com/publicaciones/14939 |
| url |
https://fisabio.portalinvestigacion.com/publicaciones/14939 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
OXFORD UNIV PRESS |
| publisher.none.fl_str_mv |
OXFORD UNIV PRESS |
| dc.source.none.fl_str_mv |
RHEUMATOLOGY ISSN: 14620324 ISSNe: 14620332 reponame:r-FISABIO. Repositorio Institucional de Producción Científica instname:Consejo Superior de Investigaciones Científicas (CSIC) |
| instname_str |
Consejo Superior de Investigaciones Científicas (CSIC) |
| reponame_str |
r-FISABIO. Repositorio Institucional de Producción Científica |
| collection |
r-FISABIO. Repositorio Institucional de Producción Científica |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869403397603459072 |
| score |
15.811543 |